drugset / Trial / NCT01401543

A Bioavailability Study of LY2452473 and Tadalafil

NCT01401543

Phase 1 Completed 24 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelTreatment

Summary

This study compares LY2452473 taken orally as a 5 milligram (mg) capsule at the same time as a 5 mg tadalafil tablet with three different combination tablets (LY900010) of 5 mg LY2452473 and 5 mg tadalafil taken orally. The study will evaluate the amount of LY2452473 and tadalafil circulating in the blood for each treatment. Side effects will be documented. This study is approximately 34 days not including screening.

Timeline

Start
2011-07
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator LY2452473 Small molecule 5 mg Oral
Subject LY900010 Unknown 5 mg Oral
Comparator Tadalafil Small molecule 5 mg Oral

Indications